Perioperative treatment and biomarker analysis of LP002, an anti‐PD‐L1 antibody, plus chemotherapy in resectable gastric and gastroesophageal junction cancer
Abstract Background The addition of immune checkpoint inhibitors to perioperative chemotherapy in operable gastric or gastroesophageal junction (GEJ) cancer has become one of the research hotspots, while reliable biomarkers for efficacy are lacking. We conducted a phase 1 trial to assess the safety...
Main Authors: | Jia‐lin Tang, Bo Zhang, Jian‐ping Xu, Ling Qi, Dao Xin, Lin Wang, Bing‐zhi Wang, Yan‐tao Tian, Yong Li, Jing Huang |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-03-01
|
Series: | Cancer Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/cam4.5414 |
Similar Items
-
Impact of Postoperative Chemotherapy in Patients with Gastric/Gastroesophageal Adenocarcinoma Treated with Perioperative Chemotherapy
by: Alexej Ballhausen, et al.
Published: (2022-03-01) -
Significance of Lauren Classification in Patients Undergoing Neoadjuvant/Perioperative Chemotherapy for Locally Advanced Gastric or Gastroesophageal Junction Cancers—Analysis from a Large Single Center Cohort in Germany
by: Rebekka Schirren, et al.
Published: (2021-01-01) -
Adjuvant Chemoradiotherapy Versus Adjuvant Chemotherapy for Stage III Gastric or Gastroesophageal Junction Cancer After D2/R0 Resection
by: Jinming Shi, et al.
Published: (2022-07-01) -
First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer
by: Selin Aktürk Esen, et al.
Published: (2022-09-01) -
Dedifferentiated Liposarcoma of the Gastroesophageal Junction
by: Gökçe AŞKAN, et al.
Published: (2018-01-01)